Summit Therapeutics (SMMT) EBITDA Margin (2017 - 2022)

Summit Therapeutics (SMMT) has 6 years of EBITDA Margin data on file, last reported at 7700.0% in Q3 2022.

• Quarterly EBITDA Margin fell 621138.0% year-over-year to 7700.0% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 268266.82% (down 26433611.0% YoY) and the FY2022 annual result came in at 10225.39%, down 546110.0% from the prior year.
• EBITDA Margin retreated to 7700.0% in Q3 2022, from 5400.85% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 76.39% in Q4 2019 to a low of 41631.58% in Q2 2021.
• A 5-year average of 7865.06% and a median of 6328.1% in 2020 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2021 — EBITDA Margin sank 3259864 bps — and 2022, when it soared 3623073 bps.
• Tracing SMMT's EBITDA Margin over 5 years: stood at 3288.59% in 2018, then soared by 102 bps to 76.39% in 2019, then plunged by 8277 bps to 6246.49% in 2020, then plunged by 66 bps to 10377.29% in 2021, then grew by 26 bps to 7700.0% in 2022.
• The last three EBITDA Margin figures came in at 7700.0% (Q3 2022), 5400.85% (Q2 2022), and 8863.2% (Q1 2022), per Business Quant data.